GH Research (NASDAQ:GHRS) Trading 3.8% Higher – What’s Next?

GH Research PLC (NASDAQ:GHRS)’s share price traded up 3.8% during trading on Wednesday . The stock traded as high as $9.60 and last traded at $9.50. 9,127 shares traded hands during trading, a decline of 88% from the average session volume of 79,000 shares. The stock had previously closed at $9.15.

Analysts Set New Price Targets

GHRS has been the subject of a number of analyst reports. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of GH Research in a report on Thursday, September 5th. JMP Securities reaffirmed a “market outperform” rating and set a $39.00 price objective on shares of GH Research in a research note on Wednesday, September 4th.

GH Research Price Performance

The stock has a 50 day moving average price of $7.75 and a two-hundred day moving average price of $10.38. The company has a market capitalization of $466.71 million, a price-to-earnings ratio of -13.39 and a beta of 0.74.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.03. Sell-side analysts forecast that GH Research PLC will post -0.85 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. raised its holdings in shares of GH Research PLC (NASDAQ:GHRS) by 11.9% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 6,251,714 shares of the company’s stock after acquiring an additional 664,381 shares during the period. RA Capital Management L.P. owned approximately 12.02% of GH Research worth $66,643,000 at the end of the most recent reporting period. 56.90% of the stock is owned by hedge funds and other institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).